Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$60.70M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
975.23%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$87.67M
Q3 2024
Cash
Q3 2024
P/E
-0.7335
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $14.76M $12.75M $4.668M $1.265M $289.0K
YoY Change 15.79% 173.16% 269.01% 337.72%
% of Gross Profit
Research & Development $54.87M $28.51M $16.91M $6.019M $4.889M
YoY Change 92.46% 68.64% 180.88% 23.11%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $69.64M $42.26M $21.57M $7.284M $5.178M
YoY Change 64.77% 95.89% 196.18% 40.67%
Operating Profit -$69.64M -$42.26M -$21.57M
YoY Change 64.77% 95.89%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $1.351M $69.00K $3.000K $0.00
YoY Change 1857.97% 2200.0%
% of Operating Profit
Other Income/Expense, Net $4.903M -$45.00K -$38.00K -$6.322M -$457.0K
YoY Change -10995.56% 18.42% -99.4% 1283.37%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$64.73M -$40.96M -$21.54M -$13.60M -$5.635M
YoY Change 58.05% 90.11% 58.37% 141.4%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$64.73M -$40.96M -$21.54M -$13.60M -$5.635M
YoY Change 58.05% 90.11% 58.37% 141.4%
Net Earnings / Revenue
Basic Earnings Per Share -$2.74 -$2.79 -$10.64
Diluted Earnings Per Share -$2.74 -$2.79 -$1.150M -$725.9K -$300.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $107.3M $96.06M $58.56M $4.070M $5.598M
YoY Change 11.7% 64.05% 1338.7% -27.3%
Cash & Equivalents $15.65M $27.22M $12.10M $4.070M $5.598M
Short-Term Investments $91.65M $68.84M $46.46M $0.00
Other Short-Term Assets $3.212M $2.562M $1.551M $164.0K $102.0K
YoY Change 25.37% 65.18% 845.73% 60.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $110.5M $98.62M $60.11M $4.234M $5.700M
YoY Change 12.05% 64.08% 1319.6% -25.72%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $27.19M $3.219M $3.486M $0.00
YoY Change 744.8% -7.66%
Other Assets $1.043M $720.0K $1.724M $0.00
YoY Change 44.86% -58.24%
Total Long-Term Assets $28.24M $3.939M $5.210M $0.00 $0.00
YoY Change 616.86% -24.4%
Total Assets $138.7M $102.6M $65.32M $4.234M $5.700M
YoY Change
Accounts Payable $2.676M $2.122M $1.063M $132.0K $51.00K
YoY Change 26.11% 99.62% 705.3% 158.82%
Accrued Expenses $10.70M $5.058M $2.315M $1.313M $108.0K
YoY Change 111.53% 118.49% 76.31% 1115.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $17.00K
YoY Change
Total Short-Term Liabilities $14.04M $7.186M $3.395M $1.459M $159.0K
YoY Change 95.42% 111.66% 132.69% 817.61%
Long-Term Debt $0.00 $0.00 $13.00K $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $2.000K $24.00K $728.0K
YoY Change -100.0% -96.7%
Total Long-Term Liabilities $0.00 $2.000K $13.00K $24.00K $728.0K
YoY Change -100.0% -84.62% -45.83% -96.7%
Total Liabilities $14.04M $7.188M $3.408M $1.483M $887.0K
YoY Change 95.37% 110.92% 129.8% 67.19%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 23.60M 15.34M 2.638M
Diluted Shares Outstanding 23.60M 15.34M 2.638M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $44.52 Million

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 41 full-time employees. The company went IPO on 2022-03-25. The firm is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

Industry: Pharmaceutical Preparations Peers: biote Corp. EyePoint Pharmaceuticals, Inc. ORAMED PHARMACEUTICALS INC. JOHNSON & JOHNSON MARINUS PHARMACEUTICALS, INC. RVL Pharmaceuticals plc Satsuma Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc. Xeris Biopharma Holdings, Inc.